Oncternal Therapeutics, Inc.

NasdaqCM:ONCT Stock Report

Market Cap: US$22.1m

Oncternal Therapeutics Future Growth

Future criteria checks 0/6

Oncternal Therapeutics's earnings are forecast to decline at 13.8% per annum while its annual revenue is expected to grow at 2.6% per year. EPS is expected to grow by 1.5% per annum.

Key information

-13.8%

Earnings growth rate

1.5%

EPS growth rate

Biotechs earnings growth20.7%
Revenue growth rate2.6%
Future return on equityn/a
Analyst coverage

Low

Last updated08 Mar 2024

Recent future growth updates

Recent updates

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Mar 03
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Nov 06
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Jul 12
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Jan 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Oncternal Therapeutics begins phase 3 study of zilovertamab

Sep 27

Oncternal Therapeutics: Selling For Under Cash Value

Sep 02

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug 09

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Jul 14

Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve

Jun 07

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Apr 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics: Trading Near Cash With Impressive Results

Jan 04

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09
Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company

Oct 10

Oncternal: Solid Data In 2 Cancers With High Unmet Need

Jun 17

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05
We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Mar 01
Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Oncternal: Solid Data In Tough-To-Treat Cancer

Jan 31

Oncternal Therapeutics: Recent Success Points To A Bright Future

Jan 29

Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary

Jan 14

Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies

Jan 07

Oncternal Therapeutics soars after presenting data at ASH

Dec 07

Oncternal Therapeutics shares dip 20% after raising 'bought deal' offering to $22.5M

Nov 18

New data on lead drug propels Oncternal Therapeutics, up 78%

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqCM:ONCT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261-56N/A-521
12/31/20251-48N/A-442
12/31/20240-34N/A-393
12/31/20231-39-32-32N/A
9/30/20231-42-35-35N/A
6/30/20231-43-41-41N/A
3/31/20231-46-39-39N/A
12/31/20221-44-37-37N/A
9/30/20222-41-34-34N/A
6/30/20224-39-29-29N/A
3/31/20224-35-29-29N/A
12/31/20214-31-27-27N/A
9/30/20215-26-24-24N/A
6/30/20214-21-23-23N/A
3/31/20214-18-19-19N/A
12/31/20203-17-17-17N/A
9/30/20203-19-17-17N/A
6/30/20202-19-15-15N/A
3/31/20203-37-17-17N/A
12/31/20192-34-17-17N/A
9/30/20192-31-16-16N/A
6/30/20192-28-12-12N/A
3/31/20193-7-7-7N/A
12/31/20183-7-7-7N/A
12/31/20172-10-9-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ONCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ONCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ONCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ONCT's revenue (2.6% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: ONCT's revenue (2.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ONCT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.